In anticipation of the upcoming SupplySide West Show in early November, Aker BioMarine Antarctic is revealing recent data from SPINS showing that krill oil has grown 43 percent in the natural products channel during the last year, significantly outpacing growth of other sources of omega-3s. ("SPINSscan Natural 52 weeks ending 7/7/12").
Aker BioMarine Antarctic, which supplies Superba brand krill ingredients, believes this growth is likely a result of the high interest in krill oil in the food, drug and mass channel, where krill supplements grew 70 percent last year. At this rate, Aker believes krill supplement sales will soon become the second largest category of omega-3 supplements in FDM.
"We are encouraged by these numbers because it signifies reinvigorated growth in the natural channel," said Eric Anderson, VP Global Marketing, Aker BioMarine. "A consumer study sponsored by Aker this year showed that nearly 4 out of 10 omega-3 supplement users are looking for an alternative omega-3 source. Krill Phospholipid Omega-3s provide an excellent user experience in the form of smaller capsules and easy digestion, both of which continue to drive repeat purchase."
Superba krill oil is a pure, natural source of EPA and DHA omega-3s. Superba's omega-3s are bound to phospholipids, which studies show are better utilized by the body compared to other omega-3 sources. Phospholipid-bound omega-3s make it into the cells and tissues more efficiently, allowing for a smaller capsule, and phospholipid-bound omega-3s are highly tolerable, free of repeating.
Aker BioMarine is the only krill ingredient marketer that is primary in its supply. Aker's proprietary Eco-Harvesting technology and on-board processing result in the unique composition of Superba krill oil and provide full traceability from sea to shelf. Aker's fisheries have been granted Marine Stewardship Council (MSC) certification, an exclusive distinction that no other krill fishery has earned.
As part of an established commitment to substantiating krill's health benefits, Aker continues to sponsor in vitro, in vivo and human clinical trials with phospholipid EPA and DHA from krill oil, consistently demonstrating a higher uptake of phospholipid omega-3 fatty acids, improved blood lipid profiles, and increased uptake of DHA in brain tissue compared to other omega-3 fatty acid sources.